Chimeric Therapeutics Ltd Market Cap ($110.00K)
Market Cap & Net Worth: Chimeric Therapeutics Ltd (CHM)
Chimeric Therapeutics Ltd market cap. Chimeric Therapeutics Ltd (AU:CHM) has a market capitalization of $110.00K (AU$155.47K) as of November 7, 2026. Listed on the AU stock exchange, this Australia-based company holds position #31498 globally and #1813 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chimeric Therapeutics Ltd's stock price AU$0.00 by its total outstanding shares 51822282 (51.82 Million). Also see how efficiently does Chimeric Therapeutics Ltd generate cash for how efficiently the company converts equity into cash flow.
Chimeric Therapeutics Ltd Market Cap History (2021–2026)
Chimeric Therapeutics Ltd market cap history from 2021 to 2026. Data shows change from $9.53 Million to $110.00K (-54.77% CAGR). Check Chimeric Therapeutics Ltd (CHM) share price today for real-time trading data and today's change.
Chimeric Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chimeric Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CHM net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.02x
Chimeric Therapeutics Ltd's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $9.53 Million | $2.65K | -$15.11 Million | 3603.01x | N/A |
| 2022 | $2.93 Million | $2.62 Million | -$15.90 Million | 1.12x | N/A |
| 2023 | $1.28 Million | $4.51 Million | -$25.92 Million | 0.28x | N/A |
| 2024 | $256.67K | $7.46 Million | -$12.53 Million | 0.03x | N/A |
| 2025 | $73.34K | $3.97 Million | -$10.43 Million | 0.02x | N/A |
Competitor Companies of CHM by Market Capitalization
Companies near Chimeric Therapeutics Ltd in the global market cap rankings as of November 7, 2026. Also see Chimeric Therapeutics Ltd balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Chimeric Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Chimeric Therapeutics Ltd (2021–2026)
Market capitalization of Chimeric Therapeutics Ltd from 2021 to today. Between 2021 and today, Chimeric Therapeutics Ltd's market cap moved from $9.53 Million to $ 110.00K, with a yearly change of -54.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$110.00K | +50.00% |
| 2025 | AU$73.34K | -71.43% |
| 2024 | AU$256.67K | -80.00% |
| 2023 | AU$1.28 Million | -56.25% |
| 2022 | AU$2.93 Million | -69.23% |
| 2021 | AU$9.53 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Chimeric Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $110.00K USD |
| MoneyControl | $110.00K USD |
| MarketWatch | $110.00K USD |
| marketcap.company | $110.00K USD |
| Reuters | $110.00K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more